Cited by 69Transplantation: Methods and OutcomesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisOrgan Donation and Transplantation

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Bilateral Lung Transplantation Offers Better Long-Term Survival, Compared With Single-Lung Transplantation, for Younger Patients With Idiopathic Pulmonary Fibrosis

Open access
Force, Seth D., Kilgo, Pat, Neujahr, David C., Pelaez, Andres, Pickens, Allan, Fernandez, Felix G., Miller, Daniel L., Lawrence, Clint·2011·The Annals of Thoracic Surgery

Abstract

Background Single-lung transplantation (SLT) and bilateral lung transplantation (BLT) are both good options for patients with end-stage lung disease secondary to idiopathic pulmonary fibrosis. It is, however, unclear whether BLT offers any survival advantage over SLT. The purpose of our study was to evaluate a large group of patients to determine if either SLT or BLT officered a long-term survival advantage for patients with IPF.Methods This was an Institutional Review Board-approved retrospective analysis of the United Network of Organ Sharing database from 1987 to 2008. Survival was determined using Kaplan-Meir estimates and the effect of laterality was determined by Cox proportional hazards and propensity analyses.Results Lung transplantation for idiopathic pulmonary fibrosis was performed in 3,860 patients (2,431 SLTs and 1429 BLTs). Multivariate and propensity analysis failed to show any survival advantage for BLT (hazard ratio = 0.90, 95% confidence interval = 0.78 to 1.0, p = 0.11). One-year conditional survival favored BLT (hazard ratio 0.73, 95% confidence interval 0.60 to 0.87, p = 0.00064). Risk factors for early death included recipient age over 57 and donor age over 36 years.Conclusions Bilateral lung transplantation should be considered for younger patients with idiopathic pulmonary fibrosis and results may be optimized when younger donors are used.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.athoracsur.2010.08.055

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Among 3,830 IPF patients in an OPTN analysis who received transplants between 1997 and 2008, patients who received BLT had significantly longer mean survival (8.34 years) compared to SLT (7.37 years), with HR for mortality 0.798 (95% CI 0.716 to 0.889).

    “Among 3,830 IPF patients included in an analysis of the OPTN data who received transplants between 1997 and 2008, patients who received a BLT had significantly (P < 0.001) longer mean survival (8.34 years) compared to patients who received a SLT (7.37 years), (HR for mortality: 0.798 [95% CI 0.716 to 0.889]) [51].”

    From Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature (2014) · cites this paper as [51]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • At five years post-transplantation, approximately 60% of BLT and 53% of SLT recipients were alive; at ten years, approximately 48% and 30% were alive.

    “At five years’ post-transplantation, approximately 60% and 53% of patients who received BLT and SLT transplants, respectively, were alive [51]. At ten years’ post-transplantation, approximately 48% and 30% of patients who received BLT and SLT transplants, respectively, were alive [51].”

    From Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature (2014) · cites this paper as [51]

    The Results (page unavailable) report an unadjusted long-term survival advantage for BLT over SLT, consistent with the direction of the cited comparison. They do not give the claimed five-year or ten-year survival percentages; searches for those rates found no matching passage in our copy. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Long-term survival conditional on surviving one year was significantly better for patients who received BLT vs. SLT (12.08 years vs. 6.8 years).

    “Long-term survival, conditional to surviving one-year, was also significantly (P < 0.0006) better for patients who received a BLT vs. SLT (12.08 years versus 6.8 years) [51].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Metadata

Authors
Force, S. D., Kilgo, P., Neujahr, D. C., Pelaez, A., Pickens, A., Fernandez, F. G., Miller, D. L., & Lawrence, C.
Affiliations
Emory University (US)
Corresponding author
Force, Seth D.
Venue
The Annals of Thoracic Surgery
Publisher
Elsevier BV
Published
2011-01
Volume
91
Issue
1
Pages
244-249
ISSN
0003-4975 (ISSN-L)
OpenAlex
W2162066400
Cited by
69
References
18
Citations by year
2025: 2 · 2024: 1 · 2023: 4 · 2022: 5 · 2021: 3 · 2020: 4 · 2019: 9 · 2018: 11 · 2017: 5 · 2016: 7 · 2015: 6 · 2014: 5 · 2013: 2 · 2012: 2
FWCI
2.37
Type
journal article
Language
en
Open access
Locations
  • The Annals of Thoracic Surgery (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Allergy and Infectious Diseases (K08AI079166)
Topics
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
Keywords
bilateral lung transplantation, single lung transplantation, idiopathic pulmonary fibrosis, long-term survival, donor age, recipient age, end-stage lung disease, transplant outcomes
MeSH terms
Adolescent, Adult, Age Factors, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Cohort Studies, Survival Rate, Survival Analysis, Lung Transplantation, Treatment Outcome, Idiopathic Pulmonary Fibrosis, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review